Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
3,902
archived clinical trials in
Irritable Bowel Syndrome (IBS)

52-Week Efficacy and Safety Study of Ibodutant in Women With Irritable Bowel Syndrome With Diarrhea (IBS-D)
A 52-Week, Double-blind, Randomised, Placebo-controlled, Parallel-group Phase III Study With Re-randomisations at Week 25 to Evaluate the Efficacy and Safety of Oral Ibodutant 10 mg Once Daily in Female Patients With Irritable Bowel Syndrome With Diarrhoea (IBS-D)
Status: Enrolling
Updated:  5/18/2016
Clinical Research Facility
569
mi
from
Houston, TX
52-Week Efficacy and Safety Study of Ibodutant in Women With Irritable Bowel Syndrome With Diarrhea (IBS-D)
A 52-Week, Double-blind, Randomised, Placebo-controlled, Parallel-group Phase III Study With Re-randomisations at Week 25 to Evaluate the Efficacy and Safety of Oral Ibodutant 10 mg Once Daily in Female Patients With Irritable Bowel Syndrome With Diarrhoea (IBS-D)
Status: Enrolling
Updated: 5/18/2016
Clinical Research Facility
569
mi
from
Houston, TX
Click here to add this to my saved trials
52-Week Efficacy and Safety Study of Ibodutant in Women With Irritable Bowel Syndrome With Diarrhea (IBS-D)
A 52-Week, Double-blind, Randomised, Placebo-controlled, Parallel-group Phase III Study With Re-randomisations at Week 25 to Evaluate the Efficacy and Safety of Oral Ibodutant 10 mg Once Daily in Female Patients With Irritable Bowel Syndrome With Diarrhoea (IBS-D)
Status: Enrolling
Updated:  5/18/2016
Clinical Research Facility
583
mi
from
San Antonio, TX
52-Week Efficacy and Safety Study of Ibodutant in Women With Irritable Bowel Syndrome With Diarrhea (IBS-D)
A 52-Week, Double-blind, Randomised, Placebo-controlled, Parallel-group Phase III Study With Re-randomisations at Week 25 to Evaluate the Efficacy and Safety of Oral Ibodutant 10 mg Once Daily in Female Patients With Irritable Bowel Syndrome With Diarrhoea (IBS-D)
Status: Enrolling
Updated: 5/18/2016
Clinical Research Facility
583
mi
from
San Antonio, TX
Click here to add this to my saved trials
52-Week Efficacy and Safety Study of Ibodutant in Women With Irritable Bowel Syndrome With Diarrhea (IBS-D)
A 52-Week, Double-blind, Randomised, Placebo-controlled, Parallel-group Phase III Study With Re-randomisations at Week 25 to Evaluate the Efficacy and Safety of Oral Ibodutant 10 mg Once Daily in Female Patients With Irritable Bowel Syndrome With Diarrhoea (IBS-D)
Status: Enrolling
Updated:  5/18/2016
Clinical Research Facility
792
mi
from
Logan, UT
52-Week Efficacy and Safety Study of Ibodutant in Women With Irritable Bowel Syndrome With Diarrhea (IBS-D)
A 52-Week, Double-blind, Randomised, Placebo-controlled, Parallel-group Phase III Study With Re-randomisations at Week 25 to Evaluate the Efficacy and Safety of Oral Ibodutant 10 mg Once Daily in Female Patients With Irritable Bowel Syndrome With Diarrhoea (IBS-D)
Status: Enrolling
Updated: 5/18/2016
Clinical Research Facility
792
mi
from
Logan, UT
Click here to add this to my saved trials
52-Week Efficacy and Safety Study of Ibodutant in Women With Irritable Bowel Syndrome With Diarrhea (IBS-D)
A 52-Week, Double-blind, Randomised, Placebo-controlled, Parallel-group Phase III Study With Re-randomisations at Week 25 to Evaluate the Efficacy and Safety of Oral Ibodutant 10 mg Once Daily in Female Patients With Irritable Bowel Syndrome With Diarrhoea (IBS-D)
Status: Enrolling
Updated:  5/18/2016
Clinical Research Facility
788
mi
from
Ogden, UT
52-Week Efficacy and Safety Study of Ibodutant in Women With Irritable Bowel Syndrome With Diarrhea (IBS-D)
A 52-Week, Double-blind, Randomised, Placebo-controlled, Parallel-group Phase III Study With Re-randomisations at Week 25 to Evaluate the Efficacy and Safety of Oral Ibodutant 10 mg Once Daily in Female Patients With Irritable Bowel Syndrome With Diarrhoea (IBS-D)
Status: Enrolling
Updated: 5/18/2016
Clinical Research Facility
788
mi
from
Ogden, UT
Click here to add this to my saved trials
52-Week Efficacy and Safety Study of Ibodutant in Women With Irritable Bowel Syndrome With Diarrhea (IBS-D)
A 52-Week, Double-blind, Randomised, Placebo-controlled, Parallel-group Phase III Study With Re-randomisations at Week 25 to Evaluate the Efficacy and Safety of Oral Ibodutant 10 mg Once Daily in Female Patients With Irritable Bowel Syndrome With Diarrhoea (IBS-D)
Status: Enrolling
Updated:  5/18/2016
Clinical Research Facility
777
mi
from
Sandy, UT
52-Week Efficacy and Safety Study of Ibodutant in Women With Irritable Bowel Syndrome With Diarrhea (IBS-D)
A 52-Week, Double-blind, Randomised, Placebo-controlled, Parallel-group Phase III Study With Re-randomisations at Week 25 to Evaluate the Efficacy and Safety of Oral Ibodutant 10 mg Once Daily in Female Patients With Irritable Bowel Syndrome With Diarrhoea (IBS-D)
Status: Enrolling
Updated: 5/18/2016
Clinical Research Facility
777
mi
from
Sandy, UT
Click here to add this to my saved trials
52-Week Efficacy and Safety Study of Ibodutant in Women With Irritable Bowel Syndrome With Diarrhea (IBS-D)
A 52-Week, Double-blind, Randomised, Placebo-controlled, Parallel-group Phase III Study With Re-randomisations at Week 25 to Evaluate the Efficacy and Safety of Oral Ibodutant 10 mg Once Daily in Female Patients With Irritable Bowel Syndrome With Diarrhoea (IBS-D)
Status: Enrolling
Updated:  5/18/2016
Clinical Research Facility
1018
mi
from
Lynchburgh, VA
52-Week Efficacy and Safety Study of Ibodutant in Women With Irritable Bowel Syndrome With Diarrhea (IBS-D)
A 52-Week, Double-blind, Randomised, Placebo-controlled, Parallel-group Phase III Study With Re-randomisations at Week 25 to Evaluate the Efficacy and Safety of Oral Ibodutant 10 mg Once Daily in Female Patients With Irritable Bowel Syndrome With Diarrhoea (IBS-D)
Status: Enrolling
Updated: 5/18/2016
Clinical Research Facility
1018
mi
from
Lynchburgh, VA
Click here to add this to my saved trials
52-Week Efficacy and Safety Study of Ibodutant in Women With Irritable Bowel Syndrome With Diarrhea (IBS-D)
A 52-Week, Double-blind, Randomised, Placebo-controlled, Parallel-group Phase III Study With Re-randomisations at Week 25 to Evaluate the Efficacy and Safety of Oral Ibodutant 10 mg Once Daily in Female Patients With Irritable Bowel Syndrome With Diarrhoea (IBS-D)
Status: Enrolling
Updated:  5/18/2016
Clinical Research Facility
1410
mi
from
Seattle, WA
52-Week Efficacy and Safety Study of Ibodutant in Women With Irritable Bowel Syndrome With Diarrhea (IBS-D)
A 52-Week, Double-blind, Randomised, Placebo-controlled, Parallel-group Phase III Study With Re-randomisations at Week 25 to Evaluate the Efficacy and Safety of Oral Ibodutant 10 mg Once Daily in Female Patients With Irritable Bowel Syndrome With Diarrhoea (IBS-D)
Status: Enrolling
Updated: 5/18/2016
Clinical Research Facility
1410
mi
from
Seattle, WA
Click here to add this to my saved trials
52-Week Efficacy and Safety Study of Ibodutant in Women With Irritable Bowel Syndrome With Diarrhea (IBS-D)
A 52-Week, Double-blind, Randomised, Placebo-controlled, Parallel-group Phase III Study With Re-randomisations at Week 25 to Evaluate the Efficacy and Safety of Oral Ibodutant 10 mg Once Daily in Female Patients With Irritable Bowel Syndrome With Diarrhoea (IBS-D)
Status: Enrolling
Updated:  5/18/2016
Clinical Research Facility
1201
mi
from
Spokane, WA
52-Week Efficacy and Safety Study of Ibodutant in Women With Irritable Bowel Syndrome With Diarrhea (IBS-D)
A 52-Week, Double-blind, Randomised, Placebo-controlled, Parallel-group Phase III Study With Re-randomisations at Week 25 to Evaluate the Efficacy and Safety of Oral Ibodutant 10 mg Once Daily in Female Patients With Irritable Bowel Syndrome With Diarrhoea (IBS-D)
Status: Enrolling
Updated: 5/18/2016
Clinical Research Facility
1201
mi
from
Spokane, WA
Click here to add this to my saved trials
52-Week Efficacy and Safety Study of Ibodutant in Women With Irritable Bowel Syndrome With Diarrhea (IBS-D)
A 52-Week, Double-blind, Randomised, Placebo-controlled, Parallel-group Phase III Study With Re-randomisations at Week 25 to Evaluate the Efficacy and Safety of Oral Ibodutant 10 mg Once Daily in Female Patients With Irritable Bowel Syndrome With Diarrhoea (IBS-D)
Status: Enrolling
Updated:  5/18/2016
5156
mi
from
Ceske Budejovice,
52-Week Efficacy and Safety Study of Ibodutant in Women With Irritable Bowel Syndrome With Diarrhea (IBS-D)
A 52-Week, Double-blind, Randomised, Placebo-controlled, Parallel-group Phase III Study With Re-randomisations at Week 25 to Evaluate the Efficacy and Safety of Oral Ibodutant 10 mg Once Daily in Female Patients With Irritable Bowel Syndrome With Diarrhoea (IBS-D)
Status: Enrolling
Updated: 5/18/2016
5156
mi
from
Ceske Budejovice,
Click here to add this to my saved trials
Partnership and Dignity: a Mixed-methods Survey on Supporting and Retaining Uganda's Village Health Teams
Partnership and Dignity: a Mixed-methods Survey on Supporting and Retaining Uganda's Village Health Teams
Status: Enrolling
Updated:  6/15/2016
The George Washington University School of Medicine and Health Sciences
1126
mi
from
Washington,
Partnership and Dignity: a Mixed-methods Survey on Supporting and Retaining Uganda's Village Health Teams
Partnership and Dignity: a Mixed-methods Survey on Supporting and Retaining Uganda's Village Health Teams
Status: Enrolling
Updated: 6/15/2016
The George Washington University School of Medicine and Health Sciences
1126
mi
from
Washington,
Click here to add this to my saved trials
Sample Collection Study to Evaluate DNA Markers in Subjects With Inflammatory Bowel Disease (IBD)
Sample Collection Study to Evaluate DNA Markers in Subjects With Inflammatory Bowel Disease (IBD)
Status: Enrolling
Updated:  8/9/2016
Digestive Health Specialists of the Southeast
834
mi
from
Dothan, AL
Sample Collection Study to Evaluate DNA Markers in Subjects With Inflammatory Bowel Disease (IBD)
Sample Collection Study to Evaluate DNA Markers in Subjects With Inflammatory Bowel Disease (IBD)
Status: Enrolling
Updated: 8/9/2016
Digestive Health Specialists of the Southeast
834
mi
from
Dothan, AL
Click here to add this to my saved trials
Sample Collection Study to Evaluate DNA Markers in Subjects With Inflammatory Bowel Disease (IBD)
Sample Collection Study to Evaluate DNA Markers in Subjects With Inflammatory Bowel Disease (IBD)
Status: Enrolling
Updated:  8/9/2016
UC San Diego Medical Center
1142
mi
from
La Jolla, CA
Sample Collection Study to Evaluate DNA Markers in Subjects With Inflammatory Bowel Disease (IBD)
Sample Collection Study to Evaluate DNA Markers in Subjects With Inflammatory Bowel Disease (IBD)
Status: Enrolling
Updated: 8/9/2016
UC San Diego Medical Center
1142
mi
from
La Jolla, CA
Click here to add this to my saved trials
Sample Collection Study to Evaluate DNA Markers in Subjects With Inflammatory Bowel Disease (IBD)
Sample Collection Study to Evaluate DNA Markers in Subjects With Inflammatory Bowel Disease (IBD)
Status: Enrolling
Updated:  8/9/2016
Facey Medical Foundation
1176
mi
from
Mission Hills, CA
Sample Collection Study to Evaluate DNA Markers in Subjects With Inflammatory Bowel Disease (IBD)
Sample Collection Study to Evaluate DNA Markers in Subjects With Inflammatory Bowel Disease (IBD)
Status: Enrolling
Updated: 8/9/2016
Facey Medical Foundation
1176
mi
from
Mission Hills, CA
Click here to add this to my saved trials
Sample Collection Study to Evaluate DNA Markers in Subjects With Inflammatory Bowel Disease (IBD)
Sample Collection Study to Evaluate DNA Markers in Subjects With Inflammatory Bowel Disease (IBD)
Status: Enrolling
Updated:  8/9/2016
Medical Research Center of Conneticut
1346
mi
from
Hamden, CT
Sample Collection Study to Evaluate DNA Markers in Subjects With Inflammatory Bowel Disease (IBD)
Sample Collection Study to Evaluate DNA Markers in Subjects With Inflammatory Bowel Disease (IBD)
Status: Enrolling
Updated: 8/9/2016
Medical Research Center of Conneticut
1346
mi
from
Hamden, CT
Click here to add this to my saved trials
Sample Collection Study to Evaluate DNA Markers in Subjects With Inflammatory Bowel Disease (IBD)
Sample Collection Study to Evaluate DNA Markers in Subjects With Inflammatory Bowel Disease (IBD)
Status: Enrolling
Updated:  8/9/2016
Edward Hines,Jr., VA Hospital
600
mi
from
Hines, IL
Sample Collection Study to Evaluate DNA Markers in Subjects With Inflammatory Bowel Disease (IBD)
Sample Collection Study to Evaluate DNA Markers in Subjects With Inflammatory Bowel Disease (IBD)
Status: Enrolling
Updated: 8/9/2016
Edward Hines,Jr., VA Hospital
600
mi
from
Hines, IL
Click here to add this to my saved trials
Sample Collection Study to Evaluate DNA Markers in Subjects With Inflammatory Bowel Disease (IBD)
Sample Collection Study to Evaluate DNA Markers in Subjects With Inflammatory Bowel Disease (IBD)
Status: Enrolling
Updated:  8/9/2016
Gastroenterology Associates
637
mi
from
Baton Rouge, LA
Sample Collection Study to Evaluate DNA Markers in Subjects With Inflammatory Bowel Disease (IBD)
Sample Collection Study to Evaluate DNA Markers in Subjects With Inflammatory Bowel Disease (IBD)
Status: Enrolling
Updated: 8/9/2016
Gastroenterology Associates
637
mi
from
Baton Rouge, LA
Click here to add this to my saved trials
Sample Collection Study to Evaluate DNA Markers in Subjects With Inflammatory Bowel Disease (IBD)
Sample Collection Study to Evaluate DNA Markers in Subjects With Inflammatory Bowel Disease (IBD)
Status: Enrolling
Updated:  8/9/2016
Delta Research Partners, LLC
484
mi
from
Monroe, LA
Sample Collection Study to Evaluate DNA Markers in Subjects With Inflammatory Bowel Disease (IBD)
Sample Collection Study to Evaluate DNA Markers in Subjects With Inflammatory Bowel Disease (IBD)
Status: Enrolling
Updated: 8/9/2016
Delta Research Partners, LLC
484
mi
from
Monroe, LA
Click here to add this to my saved trials
Sample Collection Study to Evaluate DNA Markers in Subjects With Inflammatory Bowel Disease (IBD)
Sample Collection Study to Evaluate DNA Markers in Subjects With Inflammatory Bowel Disease (IBD)
Status: Enrolling
Updated:  8/9/2016
Louisiana Research Center, LLC
429
mi
from
Shreveport, LA
Sample Collection Study to Evaluate DNA Markers in Subjects With Inflammatory Bowel Disease (IBD)
Sample Collection Study to Evaluate DNA Markers in Subjects With Inflammatory Bowel Disease (IBD)
Status: Enrolling
Updated: 8/9/2016
Louisiana Research Center, LLC
429
mi
from
Shreveport, LA
Click here to add this to my saved trials
Sample Collection Study to Evaluate DNA Markers in Subjects With Inflammatory Bowel Disease (IBD)
Sample Collection Study to Evaluate DNA Markers in Subjects With Inflammatory Bowel Disease (IBD)
Status: Enrolling
Updated:  8/9/2016
Metropolitan Gastroenterology Group, PC Chevy Chase Clinical Research
1124
mi
from
Chevy Chase, MD
Sample Collection Study to Evaluate DNA Markers in Subjects With Inflammatory Bowel Disease (IBD)
Sample Collection Study to Evaluate DNA Markers in Subjects With Inflammatory Bowel Disease (IBD)
Status: Enrolling
Updated: 8/9/2016
Metropolitan Gastroenterology Group, PC Chevy Chase Clinical Research
1124
mi
from
Chevy Chase, MD
Click here to add this to my saved trials
Sample Collection Study to Evaluate DNA Markers in Subjects With Inflammatory Bowel Disease (IBD)
Sample Collection Study to Evaluate DNA Markers in Subjects With Inflammatory Bowel Disease (IBD)
Status: Enrolling
Updated:  8/9/2016
HealthEast Midway Clinic
552
mi
from
St. Paul, MN
Sample Collection Study to Evaluate DNA Markers in Subjects With Inflammatory Bowel Disease (IBD)
Sample Collection Study to Evaluate DNA Markers in Subjects With Inflammatory Bowel Disease (IBD)
Status: Enrolling
Updated: 8/9/2016
HealthEast Midway Clinic
552
mi
from
St. Paul, MN
Click here to add this to my saved trials
Sample Collection Study to Evaluate DNA Markers in Subjects With Inflammatory Bowel Disease (IBD)
Sample Collection Study to Evaluate DNA Markers in Subjects With Inflammatory Bowel Disease (IBD)
Status: Enrolling
Updated:  8/9/2016
Gastrointestinal Associates, P.A.
572
mi
from
Jackson, MS
Sample Collection Study to Evaluate DNA Markers in Subjects With Inflammatory Bowel Disease (IBD)
Sample Collection Study to Evaluate DNA Markers in Subjects With Inflammatory Bowel Disease (IBD)
Status: Enrolling
Updated: 8/9/2016
Gastrointestinal Associates, P.A.
572
mi
from
Jackson, MS
Click here to add this to my saved trials
Sample Collection Study to Evaluate DNA Markers in Subjects With Inflammatory Bowel Disease (IBD)
Sample Collection Study to Evaluate DNA Markers in Subjects With Inflammatory Bowel Disease (IBD)
Status: Enrolling
Updated:  8/9/2016
AGA Clinical Research Associates, LLC
1252
mi
from
Egg Harbor TWP, NJ
Sample Collection Study to Evaluate DNA Markers in Subjects With Inflammatory Bowel Disease (IBD)
Sample Collection Study to Evaluate DNA Markers in Subjects With Inflammatory Bowel Disease (IBD)
Status: Enrolling
Updated: 8/9/2016
AGA Clinical Research Associates, LLC
1252
mi
from
Egg Harbor TWP, NJ
Click here to add this to my saved trials
Sample Collection Study to Evaluate DNA Markers in Subjects With Inflammatory Bowel Disease (IBD)
Sample Collection Study to Evaluate DNA Markers in Subjects With Inflammatory Bowel Disease (IBD)
Status: Enrolling
Updated:  8/9/2016
Icahn School of Medicine at Mount Sinai
mi
from
New York, NY
Sample Collection Study to Evaluate DNA Markers in Subjects With Inflammatory Bowel Disease (IBD)
Sample Collection Study to Evaluate DNA Markers in Subjects With Inflammatory Bowel Disease (IBD)
Status: Enrolling
Updated: 8/9/2016
Icahn School of Medicine at Mount Sinai
mi
from
New York, NY
Click here to add this to my saved trials
Sample Collection Study to Evaluate DNA Markers in Subjects With Inflammatory Bowel Disease (IBD)
Sample Collection Study to Evaluate DNA Markers in Subjects With Inflammatory Bowel Disease (IBD)
Status: Enrolling
Updated:  8/9/2016
Asheville Gastroenterology Associates, P.A.
857
mi
from
Asheville, NC
Sample Collection Study to Evaluate DNA Markers in Subjects With Inflammatory Bowel Disease (IBD)
Sample Collection Study to Evaluate DNA Markers in Subjects With Inflammatory Bowel Disease (IBD)
Status: Enrolling
Updated: 8/9/2016
Asheville Gastroenterology Associates, P.A.
857
mi
from
Asheville, NC
Click here to add this to my saved trials
Sample Collection Study to Evaluate DNA Markers in Subjects With Inflammatory Bowel Disease (IBD)
Sample Collection Study to Evaluate DNA Markers in Subjects With Inflammatory Bowel Disease (IBD)
Status: Enrolling
Updated:  8/9/2016
Univ of North Carolina
1043
mi
from
Chapel Hill, NC
Sample Collection Study to Evaluate DNA Markers in Subjects With Inflammatory Bowel Disease (IBD)
Sample Collection Study to Evaluate DNA Markers in Subjects With Inflammatory Bowel Disease (IBD)
Status: Enrolling
Updated: 8/9/2016
Univ of North Carolina
1043
mi
from
Chapel Hill, NC
Click here to add this to my saved trials
Sample Collection Study to Evaluate DNA Markers in Subjects With Inflammatory Bowel Disease (IBD)
Sample Collection Study to Evaluate DNA Markers in Subjects With Inflammatory Bowel Disease (IBD)
Status: Enrolling
Updated:  8/9/2016
Kinston Medical Specialists
1133
mi
from
Kinston, NC
Sample Collection Study to Evaluate DNA Markers in Subjects With Inflammatory Bowel Disease (IBD)
Sample Collection Study to Evaluate DNA Markers in Subjects With Inflammatory Bowel Disease (IBD)
Status: Enrolling
Updated: 8/9/2016
Kinston Medical Specialists
1133
mi
from
Kinston, NC
Click here to add this to my saved trials
Sample Collection Study to Evaluate DNA Markers in Subjects With Inflammatory Bowel Disease (IBD)
Sample Collection Study to Evaluate DNA Markers in Subjects With Inflammatory Bowel Disease (IBD)
Status: Enrolling
Updated:  8/9/2016
Digestive Health Specialists, Pa
971
mi
from
Winston-salem, NC
Sample Collection Study to Evaluate DNA Markers in Subjects With Inflammatory Bowel Disease (IBD)
Sample Collection Study to Evaluate DNA Markers in Subjects With Inflammatory Bowel Disease (IBD)
Status: Enrolling
Updated: 8/9/2016
Digestive Health Specialists, Pa
971
mi
from
Winston-salem, NC
Click here to add this to my saved trials
Sample Collection Study to Evaluate DNA Markers in Subjects With Inflammatory Bowel Disease (IBD)
Sample Collection Study to Evaluate DNA Markers in Subjects With Inflammatory Bowel Disease (IBD)
Status: Enrolling
Updated:  8/9/2016
UC Health
728
mi
from
Cincinnati, OH
Sample Collection Study to Evaluate DNA Markers in Subjects With Inflammatory Bowel Disease (IBD)
Sample Collection Study to Evaluate DNA Markers in Subjects With Inflammatory Bowel Disease (IBD)
Status: Enrolling
Updated: 8/9/2016
UC Health
728
mi
from
Cincinnati, OH
Click here to add this to my saved trials
Sample Collection Study to Evaluate DNA Markers in Subjects With Inflammatory Bowel Disease (IBD)
Sample Collection Study to Evaluate DNA Markers in Subjects With Inflammatory Bowel Disease (IBD)
Status: Enrolling
Updated:  8/9/2016
Cleveland Clinic
898
mi
from
Cleveland, OH
Sample Collection Study to Evaluate DNA Markers in Subjects With Inflammatory Bowel Disease (IBD)
Sample Collection Study to Evaluate DNA Markers in Subjects With Inflammatory Bowel Disease (IBD)
Status: Enrolling
Updated: 8/9/2016
Cleveland Clinic
898
mi
from
Cleveland, OH
Click here to add this to my saved trials
Sample Collection Study to Evaluate DNA Markers in Subjects With Inflammatory Bowel Disease (IBD)
Sample Collection Study to Evaluate DNA Markers in Subjects With Inflammatory Bowel Disease (IBD)
Status: Enrolling
Updated:  8/9/2016
Vanderbilt University Medical Center
618
mi
from
Nashville, TN
Sample Collection Study to Evaluate DNA Markers in Subjects With Inflammatory Bowel Disease (IBD)
Sample Collection Study to Evaluate DNA Markers in Subjects With Inflammatory Bowel Disease (IBD)
Status: Enrolling
Updated: 8/9/2016
Vanderbilt University Medical Center
618
mi
from
Nashville, TN
Click here to add this to my saved trials
Sample Collection Study to Evaluate DNA Markers in Subjects With Inflammatory Bowel Disease (IBD)
Sample Collection Study to Evaluate DNA Markers in Subjects With Inflammatory Bowel Disease (IBD)
Status: Enrolling
Updated:  8/9/2016
Charlottesville Medical Research Center, LLC
1053
mi
from
Charlottesville, VA
Sample Collection Study to Evaluate DNA Markers in Subjects With Inflammatory Bowel Disease (IBD)
Sample Collection Study to Evaluate DNA Markers in Subjects With Inflammatory Bowel Disease (IBD)
Status: Enrolling
Updated: 8/9/2016
Charlottesville Medical Research Center, LLC
1053
mi
from
Charlottesville, VA
Click here to add this to my saved trials
Sample Collection Study to Evaluate DNA Markers in Subjects With Inflammatory Bowel Disease (IBD)
Sample Collection Study to Evaluate DNA Markers in Subjects With Inflammatory Bowel Disease (IBD)
Status: Enrolling
Updated:  8/9/2016
Gastroenterology Associates of Tidewater
1186
mi
from
Chesapeake, VA
Sample Collection Study to Evaluate DNA Markers in Subjects With Inflammatory Bowel Disease (IBD)
Sample Collection Study to Evaluate DNA Markers in Subjects With Inflammatory Bowel Disease (IBD)
Status: Enrolling
Updated: 8/9/2016
Gastroenterology Associates of Tidewater
1186
mi
from
Chesapeake, VA
Click here to add this to my saved trials
Sample Collection Study to Evaluate DNA Markers in Subjects With Inflammatory Bowel Disease (IBD)
Sample Collection Study to Evaluate DNA Markers in Subjects With Inflammatory Bowel Disease (IBD)
Status: Enrolling
Updated:  8/9/2016
Blue Ridge Medical Research
1021
mi
from
Lynchburg, VA
Sample Collection Study to Evaluate DNA Markers in Subjects With Inflammatory Bowel Disease (IBD)
Sample Collection Study to Evaluate DNA Markers in Subjects With Inflammatory Bowel Disease (IBD)
Status: Enrolling
Updated: 8/9/2016
Blue Ridge Medical Research
1021
mi
from
Lynchburg, VA
Click here to add this to my saved trials
Sample Collection Study to Evaluate DNA Markers in Subjects With Inflammatory Bowel Disease (IBD)
Sample Collection Study to Evaluate DNA Markers in Subjects With Inflammatory Bowel Disease (IBD)
Status: Enrolling
Updated:  8/9/2016
University of Wisconsin Hospital and Clinics
574
mi
from
Madison, WI
Sample Collection Study to Evaluate DNA Markers in Subjects With Inflammatory Bowel Disease (IBD)
Sample Collection Study to Evaluate DNA Markers in Subjects With Inflammatory Bowel Disease (IBD)
Status: Enrolling
Updated: 8/9/2016
University of Wisconsin Hospital and Clinics
574
mi
from
Madison, WI
Click here to add this to my saved trials
Sample Collection Study to Evaluate DNA Markers in Subjects With Inflammatory Bowel Disease (IBD)
Sample Collection Study to Evaluate DNA Markers in Subjects With Inflammatory Bowel Disease (IBD)
Status: Enrolling
Updated:  8/9/2016
Wisconsin Center for Advanced Research
633
mi
from
Milwaukee, WI
Sample Collection Study to Evaluate DNA Markers in Subjects With Inflammatory Bowel Disease (IBD)
Sample Collection Study to Evaluate DNA Markers in Subjects With Inflammatory Bowel Disease (IBD)
Status: Enrolling
Updated: 8/9/2016
Wisconsin Center for Advanced Research
633
mi
from
Milwaukee, WI
Click here to add this to my saved trials
Sample Collection Study to Evaluate DNA Markers in Subjects With Inflammatory Bowel Disease (IBD)
Sample Collection Study to Evaluate DNA Markers in Subjects With Inflammatory Bowel Disease (IBD)
Status: Enrolling
Updated:  8/9/2016
Boston Med Ctr
1443
mi
from
Boston, MA
Sample Collection Study to Evaluate DNA Markers in Subjects With Inflammatory Bowel Disease (IBD)
Sample Collection Study to Evaluate DNA Markers in Subjects With Inflammatory Bowel Disease (IBD)
Status: Enrolling
Updated: 8/9/2016
Boston Med Ctr
1443
mi
from
Boston, MA
Click here to add this to my saved trials
Sample Collection Study to Evaluate DNA Markers in Subjects With Inflammatory Bowel Disease (IBD)
Sample Collection Study to Evaluate DNA Markers in Subjects With Inflammatory Bowel Disease (IBD)
Status: Enrolling
Updated:  8/9/2016
The Mayo Clinic
515
mi
from
Rochester, MN
Sample Collection Study to Evaluate DNA Markers in Subjects With Inflammatory Bowel Disease (IBD)
Sample Collection Study to Evaluate DNA Markers in Subjects With Inflammatory Bowel Disease (IBD)
Status: Enrolling
Updated: 8/9/2016
The Mayo Clinic
515
mi
from
Rochester, MN
Click here to add this to my saved trials
Sample Collection Study to Evaluate DNA Markers in Subjects With Inflammatory Bowel Disease (IBD)
Sample Collection Study to Evaluate DNA Markers in Subjects With Inflammatory Bowel Disease (IBD)
Status: Enrolling
Updated:  8/9/2016
University of Calgary - Division of Gastroenterology
1214
mi
from
Calgary,
Sample Collection Study to Evaluate DNA Markers in Subjects With Inflammatory Bowel Disease (IBD)
Sample Collection Study to Evaluate DNA Markers in Subjects With Inflammatory Bowel Disease (IBD)
Status: Enrolling
Updated: 8/9/2016
University of Calgary - Division of Gastroenterology
1214
mi
from
Calgary,
Click here to add this to my saved trials
Treatment Response of Injectafer vs. Oral Iron to Baseline Hepcidin Levels in Patients With Iron Deficiency Anemia (IDA) Secondary to Inflammatory Bowel Disease (IBD) or Gastric Bypass
A Multi-center, Randomized, Open-label, Controlled Study to Investigate the Treatment Response of Intravenous Injectafer vs. Oral Iron to Baseline Hepcidin Levels in Patients With Iron Deficiency Anemia (IDA) Secondary to Inflammatory Bowel Disease (IBD) or Gastric Bypass
Status: Enrolling
Updated:  8/10/2016
Luitpold Pharmaceuticals, Inc.
1213
mi
from
Norristown, PA
Treatment Response of Injectafer vs. Oral Iron to Baseline Hepcidin Levels in Patients With Iron Deficiency Anemia (IDA) Secondary to Inflammatory Bowel Disease (IBD) or Gastric Bypass
A Multi-center, Randomized, Open-label, Controlled Study to Investigate the Treatment Response of Intravenous Injectafer vs. Oral Iron to Baseline Hepcidin Levels in Patients With Iron Deficiency Anemia (IDA) Secondary to Inflammatory Bowel Disease (IBD) or Gastric Bypass
Status: Enrolling
Updated: 8/10/2016
Luitpold Pharmaceuticals, Inc.
1213
mi
from
Norristown, PA
Click here to add this to my saved trials
Integrating Targeted MedlinePlus Health Prescriptions Into Clinic Practice Workflow
Integrating Targeted MedlinePlus Health Prescriptions Into Clinic Practice Workflow
Status: Enrolling
Updated:  8/15/2016
University of Missouri, Department of Internal Medicine
306
mi
from
Columbia, MO
Integrating Targeted MedlinePlus Health Prescriptions Into Clinic Practice Workflow
Integrating Targeted MedlinePlus Health Prescriptions Into Clinic Practice Workflow
Status: Enrolling
Updated: 8/15/2016
University of Missouri, Department of Internal Medicine
306
mi
from
Columbia, MO
Click here to add this to my saved trials
A Study to Evaluate the Safety and Efficacy of Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease Who Have Failed or Are Intolerant to Tumor Necrosis Factor (TNF) Antagonist Therapy (UNITI-1)
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Subjects With Moderately to Severely Active Crohn's Disease Who Have Failed or Are Intolerant to TNF Antagonist Therapy (UNITI-1)
Status: Enrolling
Updated:  10/14/2016
Clinical Research Facility
805
mi
from
Decatur, GA
A Study to Evaluate the Safety and Efficacy of Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease Who Have Failed or Are Intolerant to Tumor Necrosis Factor (TNF) Antagonist Therapy (UNITI-1)
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Subjects With Moderately to Severely Active Crohn's Disease Who Have Failed or Are Intolerant to TNF Antagonist Therapy (UNITI-1)
Status: Enrolling
Updated: 10/14/2016
Clinical Research Facility
805
mi
from
Decatur, GA
Click here to add this to my saved trials
A Study to Evaluate the Safety and Efficacy of Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease Who Have Failed or Are Intolerant to Tumor Necrosis Factor (TNF) Antagonist Therapy (UNITI-1)
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Subjects With Moderately to Severely Active Crohn's Disease Who Have Failed or Are Intolerant to TNF Antagonist Therapy (UNITI-1)
Status: Enrolling
Updated:  10/14/2016
Clinical Research Facility
657
mi
from
Louisville, KY
A Study to Evaluate the Safety and Efficacy of Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease Who Have Failed or Are Intolerant to Tumor Necrosis Factor (TNF) Antagonist Therapy (UNITI-1)
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Subjects With Moderately to Severely Active Crohn's Disease Who Have Failed or Are Intolerant to TNF Antagonist Therapy (UNITI-1)
Status: Enrolling
Updated: 10/14/2016
Clinical Research Facility
657
mi
from
Louisville, KY
Click here to add this to my saved trials
A Study to Evaluate the Safety and Efficacy of Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease Who Have Failed or Are Intolerant to Tumor Necrosis Factor (TNF) Antagonist Therapy (UNITI-1)
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Subjects With Moderately to Severely Active Crohn's Disease Who Have Failed or Are Intolerant to TNF Antagonist Therapy (UNITI-1)
Status: Enrolling
Updated:  10/14/2016
Clinical Research Facility
1148
mi
from
Baltimore, MD
A Study to Evaluate the Safety and Efficacy of Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease Who Have Failed or Are Intolerant to Tumor Necrosis Factor (TNF) Antagonist Therapy (UNITI-1)
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Subjects With Moderately to Severely Active Crohn's Disease Who Have Failed or Are Intolerant to TNF Antagonist Therapy (UNITI-1)
Status: Enrolling
Updated: 10/14/2016
Clinical Research Facility
1148
mi
from
Baltimore, MD
Click here to add this to my saved trials
A Study to Evaluate the Safety and Efficacy of Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease Who Have Failed or Are Intolerant to Tumor Necrosis Factor (TNF) Antagonist Therapy (UNITI-1)
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Subjects With Moderately to Severely Active Crohn's Disease Who Have Failed or Are Intolerant to TNF Antagonist Therapy (UNITI-1)
Status: Enrolling
Updated:  10/14/2016
Clinical Research Facility
1444
mi
from
Boston, MA
A Study to Evaluate the Safety and Efficacy of Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease Who Have Failed or Are Intolerant to Tumor Necrosis Factor (TNF) Antagonist Therapy (UNITI-1)
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Subjects With Moderately to Severely Active Crohn's Disease Who Have Failed or Are Intolerant to TNF Antagonist Therapy (UNITI-1)
Status: Enrolling
Updated: 10/14/2016
Clinical Research Facility
1444
mi
from
Boston, MA
Click here to add this to my saved trials
A Study to Evaluate the Safety and Efficacy of Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease Who Have Failed or Are Intolerant to Tumor Necrosis Factor (TNF) Antagonist Therapy (UNITI-1)
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Subjects With Moderately to Severely Active Crohn's Disease Who Have Failed or Are Intolerant to TNF Antagonist Therapy (UNITI-1)
Status: Enrolling
Updated:  10/14/2016
Clinical Research Facility
808
mi
from
Ann Arbor, MI
A Study to Evaluate the Safety and Efficacy of Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease Who Have Failed or Are Intolerant to Tumor Necrosis Factor (TNF) Antagonist Therapy (UNITI-1)
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Subjects With Moderately to Severely Active Crohn's Disease Who Have Failed or Are Intolerant to TNF Antagonist Therapy (UNITI-1)
Status: Enrolling
Updated: 10/14/2016
Clinical Research Facility
808
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
A Study to Evaluate the Safety and Efficacy of Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease Who Have Failed or Are Intolerant to Tumor Necrosis Factor (TNF) Antagonist Therapy (UNITI-1)
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Subjects With Moderately to Severely Active Crohn's Disease Who Have Failed or Are Intolerant to TNF Antagonist Therapy (UNITI-1)
Status: Enrolling
Updated:  10/14/2016
Clinical Research Facility
515
mi
from
Rochester, MN
A Study to Evaluate the Safety and Efficacy of Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease Who Have Failed or Are Intolerant to Tumor Necrosis Factor (TNF) Antagonist Therapy (UNITI-1)
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Subjects With Moderately to Severely Active Crohn's Disease Who Have Failed or Are Intolerant to TNF Antagonist Therapy (UNITI-1)
Status: Enrolling
Updated: 10/14/2016
Clinical Research Facility
515
mi
from
Rochester, MN
Click here to add this to my saved trials
A Study to Evaluate the Safety and Efficacy of Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease Who Have Failed or Are Intolerant to Tumor Necrosis Factor (TNF) Antagonist Therapy (UNITI-1)
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Subjects With Moderately to Severely Active Crohn's Disease Who Have Failed or Are Intolerant to TNF Antagonist Therapy (UNITI-1)
Status: Enrolling
Updated:  10/14/2016
Clinical Research Facility
1393
mi
from
Lebanon, NH
A Study to Evaluate the Safety and Efficacy of Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease Who Have Failed or Are Intolerant to Tumor Necrosis Factor (TNF) Antagonist Therapy (UNITI-1)
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Subjects With Moderately to Severely Active Crohn's Disease Who Have Failed or Are Intolerant to TNF Antagonist Therapy (UNITI-1)
Status: Enrolling
Updated: 10/14/2016
Clinical Research Facility
1393
mi
from
Lebanon, NH
Click here to add this to my saved trials
A Study to Evaluate the Safety and Efficacy of Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease Who Have Failed or Are Intolerant to Tumor Necrosis Factor (TNF) Antagonist Therapy (UNITI-1)
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Subjects With Moderately to Severely Active Crohn's Disease Who Have Failed or Are Intolerant to TNF Antagonist Therapy (UNITI-1)
Status: Enrolling
Updated:  10/14/2016
Clinical Research Facility
1290
mi
from
New York, NY
A Study to Evaluate the Safety and Efficacy of Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease Who Have Failed or Are Intolerant to Tumor Necrosis Factor (TNF) Antagonist Therapy (UNITI-1)
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Subjects With Moderately to Severely Active Crohn's Disease Who Have Failed or Are Intolerant to TNF Antagonist Therapy (UNITI-1)
Status: Enrolling
Updated: 10/14/2016
Clinical Research Facility
1290
mi
from
New York, NY
Click here to add this to my saved trials
A Study to Evaluate the Safety and Efficacy of Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease Who Have Failed or Are Intolerant to Tumor Necrosis Factor (TNF) Antagonist Therapy (UNITI-1)
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Subjects With Moderately to Severely Active Crohn's Disease Who Have Failed or Are Intolerant to TNF Antagonist Therapy (UNITI-1)
Status: Enrolling
Updated:  10/14/2016
Clinical Research Facility
895
mi
from
Cleveland, OH
A Study to Evaluate the Safety and Efficacy of Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease Who Have Failed or Are Intolerant to Tumor Necrosis Factor (TNF) Antagonist Therapy (UNITI-1)
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Subjects With Moderately to Severely Active Crohn's Disease Who Have Failed or Are Intolerant to TNF Antagonist Therapy (UNITI-1)
Status: Enrolling
Updated: 10/14/2016
Clinical Research Facility
895
mi
from
Cleveland, OH
Click here to add this to my saved trials
A Study to Evaluate the Safety and Efficacy of Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease Who Have Failed or Are Intolerant to Tumor Necrosis Factor (TNF) Antagonist Therapy (UNITI-1)
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Subjects With Moderately to Severely Active Crohn's Disease Who Have Failed or Are Intolerant to TNF Antagonist Therapy (UNITI-1)
Status: Enrolling
Updated:  10/14/2016
Clinical Research Facility
1225
mi
from
Philadelphia, PA
A Study to Evaluate the Safety and Efficacy of Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease Who Have Failed or Are Intolerant to Tumor Necrosis Factor (TNF) Antagonist Therapy (UNITI-1)
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Safety and Efficacy of Ustekinumab Induction Therapy in Subjects With Moderately to Severely Active Crohn's Disease Who Have Failed or Are Intolerant to TNF Antagonist Therapy (UNITI-1)
Status: Enrolling
Updated: 10/14/2016
Clinical Research Facility
1225
mi
from
Philadelphia, PA
Click here to add this to my saved trials